Research and Clinical Trials

Brief Description  
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of MK-5172 when administered with peg-interferon alfa-2b and Ribavirin in treatment naive genotype 1 hepatitis C infected patients. All study patients will receive triple therapy treatment.
Who may be Eligible  
Adult men and women 18 years of age and older with genotype 1 chronic Hepatitis C infection that have not received prior treatment. Participants may not have cirrhosis of the liver.
IRB Number  
Principal Investigator  
Russo, Mark

For More Information, Contact  Regina  , McFadden
Phone:  (704) 355-7608  Fax:  (704) 355-9641  
Address:1300 Scott Avenue Charlotte, NC